Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study
Language English Country Netherlands Media print-electronic
Document type Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
19249105
DOI
10.1016/j.jad.2009.01.032
PII: S0165-0327(09)00068-8
Knihovny.cz E-resources
- MeSH
- Antidepressive Agents, Second-Generation adverse effects therapeutic use MeSH
- Cyclohexanols adverse effects therapeutic use MeSH
- Depressive Disorder, Major diagnosis physiopathology psychology therapy MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Middle Aged MeSH
- Humans MeSH
- Prefrontal Cortex drug effects physiopathology MeSH
- Psychometrics MeSH
- Personality Assessment statistics & numerical data MeSH
- Transcranial Magnetic Stimulation methods MeSH
- Venlafaxine Hydrochloride MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Antidepressive Agents, Second-Generation MeSH
- Cyclohexanols MeSH
- Venlafaxine Hydrochloride MeSH
BACKGROUND: Previous studies have shown effectiveness of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. This double-blind study compared efficacy of l Hz rTMS over the right prefrontal dorsolateral cortex with venlafaxine ER in the treatment of resistant depression. METHODS: A total of 60 inpatients with depressive disorder (DSM-IV criteria), who previously did not respond to at least one antidepressant treatment, were randomly assigned to 1 Hz rTMS with placebo and venlafaxine ER with sham rTMS for 4 weeks. The primary outcome measure was score change in the Montgomery-Asberg Depression Rating Scale (MADRS). We also used Clinical Global Impression (CGI) and Beck Depressive. Inventory-Short Form (BDI-SF). The response was defined as a >or=50% reduction of MADRS score. RESULTS: There were no significant differences between treatment groups in MADRS (p=0.38), BDI-SF (p=0.56) and CGI (p=0.17) scores from baseline to endpoint. Response rates for rTMS (33%) and venlafaxine (39%) as well as remission (MADRS score
References provided by Crossref.org
